Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Role of cardiac power in heart failure.
Cotter G, Williams SG, Vered Z, Tan LB. Cotter G, et al. Curr Opin Cardiol. 2003 May;18(3):215-22. doi: 10.1097/00001573-200305000-00007. Curr Opin Cardiol. 2003. PMID: 12826823 Review.
Effect of nitric oxide synthase inhibition on haemodynamics and outcome of patients with persistent cardiogenic shock complicating acute myocardial infarction: a phase II dose-ranging study.
Dzavík V, Cotter G, Reynolds HR, Alexander JH, Ramanathan K, Stebbins AL, Hathaway D, Farkouh ME, Ohman EM, Baran DA, Prondzinsky R, Panza JA, Cantor WJ, Vered Z, Buller CE, Kleiman NS, Webb JG, Holmes DR, Parrillo JE, Hazen SL, Gross SS, Harrington RA, Hochman JS; SHould we inhibit nitric Oxide synthase in Cardiogenic shocK 2 (SHOCK-2) investigators. Dzavík V, et al. Among authors: cotter g. Eur Heart J. 2007 May;28(9):1109-16. doi: 10.1093/eurheartj/ehm075. Epub 2007 Apr 25. Eur Heart J. 2007. PMID: 17459901 Clinical Trial.
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Torre-Amione G, Young JB, Colucci WS, Lewis BS, Pratt C, Cotter G, Stangl K, Elkayam U, Teerlink JR, Frey A, Rainisio M, Kobrin I. Torre-Amione G, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jul 2;42(1):140-7. doi: 10.1016/s0735-1097(03)00556-4. J Am Coll Cardiol. 2003. PMID: 12849674 Free article. Clinical Trial.
The predictive value of short-term changes in hemoglobin concentration in patients presenting with acute decompensated heart failure.
van der Meer P, Postmus D, Ponikowski P, Cleland JG, O'Connor CM, Cotter G, Metra M, Davison BA, Givertz MM, Mansoor GA, Teerlink JR, Massie BM, Hillege HL, Voors AA. van der Meer P, et al. Among authors: cotter g. J Am Coll Cardiol. 2013 May 14;61(19):1973-81. doi: 10.1016/j.jacc.2012.12.050. Epub 2013 Mar 14. J Am Coll Cardiol. 2013. PMID: 23500313 Free article. Clinical Trial.
RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study.
Kaluski E, Kobrin I, Zimlichman R, Marmor A, Krakov O, Milo O, Frey A, Kaplan S, Krakover R, Caspi A, Vered Z, Cotter G. Kaluski E, et al. Among authors: cotter g. J Am Coll Cardiol. 2003 Jan 15;41(2):204-10. doi: 10.1016/s0735-1097(02)02708-0. J Am Coll Cardiol. 2003. PMID: 12535809 Free article. Clinical Trial.
Clinical and hemodynamic effects of bosentan dose optimization in symptomatic heart failure patients with severe systolic dysfunction, associated with secondary pulmonary hypertension--a multi-center randomized study.
Kaluski E, Cotter G, Leitman M, Milo-Cotter O, Krakover R, Kobrin I, Moriconi T, Rainisio M, Caspi A, Reizin L, Zimlichman R, Vered Z. Kaluski E, et al. Among authors: cotter g. Cardiology. 2008;109(4):273-80. doi: 10.1159/000107791. Epub 2007 Sep 17. Cardiology. 2008. PMID: 17873492 Clinical Trial.
'Death and life are in the power of the tongue'?
Kaluski E, Milo-Cotter O, Cotter G. Kaluski E, et al. Among authors: cotter g. Cardiology. 2009;114(1):39-41. doi: 10.1159/000212059. Epub 2009 Apr 9. Cardiology. 2009. PMID: 19365112 No abstract available.
Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function).
Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM. Voors AA, et al. Among authors: cotter g. J Am Coll Cardiol. 2011 May 10;57(19):1899-907. doi: 10.1016/j.jacc.2010.11.057. J Am Coll Cardiol. 2011. PMID: 21545947 Free article. Clinical Trial.
332 results